Abstract
Cefixime was 8 to 10 times more active than cefaclor and augmentin against isolates ofEscherichia coli, Klebsiella pneumoniae andSalmonella typhi, MIC90 values ranging from 0.06 to 0.25 µg/ml. However, none of these three drugs was particularly active against isolates of more resistant gram-negative bacilli such asEnterobacter, Serratia, Citrobacter, Acinetobacter, Providencia andAchromobacter spp. The lowest MIC values for gram-negative bacilli were seen with ciprofloxacin, except for isolates ofAcinetobacter, where cotrimoxazole was the most active of the five drugs studied. Augmentin and ciprofloxacin exhibited the lowest MICs for isolates of streptococci and corynebacteria. Although cefixime may be among the most active oral betalactam drugs, it does not appear to be useful for treatment of infections caused by more resistant gram-negative bacilli.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Silver, M. S., Counts, G. W., Zeleznik, D., Turck, M. Comparison of in vitro antibacterial activity of three oral cephalosporins: cefaclor, cephalexin, and cephradine. Antimicrobial Agents and Chemotherapy 1977, 12: 591–596.
Brittain, D. C., Scully, R. E., Hirose, T., Neu, H. C. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clinical Pharmacology and Therapeutics 1985, 38: 590–594.
Neu, H. C., Chin, N., Lobthavikul, P. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrobial Agents and Chemotherapy 1984, 26: 174–180.
National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Tentative standard. M7-T. National Committee for Laboratory Standards, Villanova, PA, 1983.
Steers, E., Foltz, E. L., Graves, B. S. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antimicrobial Agents and Chemotherapy 1959, 9: 307–311.
Mulligan, M. E., Kwok, Y. Y. In vitro activity of cefixime and six other agents against nosocomial pathogens of theEnterobacteriaceae family. Infection Control 1987, 8: 241–244.
Bergeron, M. G., Tucotte, A. Penetration of cefixime into fibrin clots and in vivo efficacy againstEscherichia coli, Klebsiella pneumoniae, andStaphylococcus aureus. Antimicrobial Agents and Chemotherapy 1986, 30: 913–916.
Leitner, F., Pursiano, T. A., Buck, R. E., Tsai, Y. H., Chisolm, D. R., Misiek, M., Desiderio, J. V., Kessler, R. E. BMY 28100, a new oral cephalosporin. Antimicrobial Agents and Chemotherapy 1987, 31: 238–243.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Counts, G.W., Baugher, L.K., Ulness, B.K. et al. Comparative in vitro activity of the new oral cephalosporin cefixime. Eur. J. Clin. Microbiol. Infect. Dis. 7, 428–431 (1988). https://doi.org/10.1007/BF01962357
Issue Date:
DOI: https://doi.org/10.1007/BF01962357